Komatsu Shares Hit Record High on Unexpected Buyback Plan
By Ronnie Harui
Komatsu Ltd.'s shares rose sharply to a record high after the company unveiled an unexpected plan to buy back its common shares and reported better-than-expected net profit.
Shares were recently 10.1% higher at 4,693 yen ($30.02) in Tokyo on Tuesday, following a Japanese public holiday on Monday. The shares earlier rose as high as Y4,725, an all-time high based on data from Quick.
The Japanese construction machinery manufacturer said in a filing with the Tokyo Stock Exchange last Friday that it intends buy back up to 33 million common shares for a maximum amount of Y100 billion, starting today through Sept. 30.
In a separate filing, Komatsu said its net profit for the fiscal year that ended March 31 jumped 20.5% on year to Y393.43 billion, beating the Y389.15 billion expected in a poll of analysts by FactSet. Its revenue rose 9.1% on year to Y3.865 trillion.
Komatsu's announcement of a Y100-billion buyback is a positive surprise, said Citi Research analyst Graeme McDonald in a recent research report. The company's earnings for the fourth quarter of the fiscal year that ended March 31 were also solid, the analyst added.
Write to Ronnie Harui at ronnie.harui@wsj.com
(END) Dow Jones Newswires
April 29, 2024 22:57 ET (02:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks